Hengrui Pharma Third-Quarter Profit Rises 88.9% on Licensing Deals
China's Jiangsu Hengrui Pharmaceuticals reported an 88.9% increase in third-quarter 2026 profit, driven by income from out-licensing deals.
Jiangsu Hengrui Pharmaceuticals SSE:600276, China's biggest drugmaker by market value, reported on Tuesday a rise of 88.9% in profit for the third quarter of 2026, driven by income from out-licensing deals.